Radiation plus two drugs for intermediate-risk head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of head and neck cancer called squamous cell carcinoma (in the mouth, throat, or voice box). If your cancer is in the throat, it must test negative for a protein called p16.
- You have already had surgery to remove the cancer, and your doctor found at least one 'intermediate risk' feature, like a close surgical margin, spread to lymph nodes, or invasion into nearby tissues.
- Your general health is good enough for daily activities (fully or mildly limited).
- Your blood test results are within acceptable ranges—for example, your hemoglobin is at least 80 g/L, and your liver and kidney function are adequate.
- You have not had previous treatment with certain immune-based therapies or anti-EGFR drugs (like nimotuzumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.